Vericel Corporation (VCEL) Stock

Understand Vericel Corporation: how it makes money

Vericel develops and commercializes cellular therapies for sports medicine and severe burn care, selling autologous products such as MACI for knee cartilage repair and Epicel and NexoBrid for burn treatment, with revenue driven by product net sales and related buy-and-bill style orders by treated patients and clinical centers.

Vericel’s profit model depends on whether the company can convert a growing base of trained surgeons and approved burn centers into actual product ordering and patient treatments for MACI and its burn care therapies.

Business quality (Weak): Gross margin is high (72.0%), but the quarter still showed an operating loss (operating margin of -11.8%), even though the company also reports 11 consecutive quarters of positive non-GAAP adjusted earnings before interest, taxes, depreciation and amortization and 10 periods with positive non-GAAP adjusted earnings before interest, taxes, depreciation and amortization and operating cash flow.

Valuation: At 80× earnings, VCEL trades 377% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

• Adoption pipeline is measurable: Management tracks progress toward MACI use through “Approximately MACI Arthro Surgeons Trained to Date,” which supports visibility into future usage if training converts into treatments.
• Burn centers moving from submission to initial orders: Burn adoption progress is tracked by “Burn Centers Obtaining Pharmacy and Therapeutics Committee Approval and Placing Initial Orders,” which can indicate incremental opportunities for burn therapy ordering.
• Non-GAAP operating profitability trend: The company shows “Consecutive Quarters of Positive Non-GAAP Adjusted Earnings Before Interest Taxes Depreciation and Amortization” (11), and also reports a “Straight Quarter Count of Positive Non-GAAP Adjusted Earnings Before Interest Taxes Depreciation and Amortization and Operating Cash Flow” (10).

Bear case

• Operating loss continues: The latest quarter shows an operating margin of -11.8%, indicating costs exceeded operating revenue during the period.
• NexoBrid revenue is currently shown as zero: In the provided segment data for the quarter, “NexoBrid Net Revenue” and related items such as initial stocking and BARDA procurement revenues are shown as 0.0B, suggesting limited contribution from this product to revenue in the quarter.
• Commercial execution risk tied to center and clinician conversion: Key operating progress relies on processes such as surgeon training and burn center Pharmacy and Therapeutics Committee submissions and approvals, and conversion into orders is not guaranteed.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Tarsus Pharmaceuticals, Inc. (TARS)
• Beam Therapeutics Inc. (BEAM)
• Kodiak Sciences Inc. (KOD)
• BioCryst Pharmaceuticals, Inc. (BCRX)
• ADMA Biologics, Inc. (ADMA)
• Hemab Therapeutics Holdings, Inc. (COAG)
• Recursion Pharmaceuticals, Inc. (RXRX)
• Taysha Gene Therapies, Inc. (TSHA)